Trials / Completed
CompletedNCT03220165
Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196
An Open-Label, Single-Radiolabeled Dose, Non-Randomized Study to Determine the Mass Balance of [14C] MGL-3196
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Madrigal Pharmaceuticals, Inc. · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is determine in healthy males how MGL-3196 is metabolized using a radio-labeled version of MGL-3196.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MGL-3196 | oral, 100 mg |
Timeline
- Start date
- 2017-08-06
- Primary completion
- 2017-09-03
- Completion
- 2017-09-03
- First posted
- 2017-07-18
- Last updated
- 2017-12-19
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03220165. Inclusion in this directory is not an endorsement.